Nang Kuang Pharmaceutical Co (TPE:1752) Beneish M-Score: -2.95 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1752 Nang Kuang Pharmaceutical Co Ltd TPE:1752
88 GF Score
Price NT$31.35
GF Value NT$46.62
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Nang Kuang Pharmaceutical Co Beneish M-Score?

Nang Kuang Pharmaceutical Co TPE:1752 -1.10% 88 Beneish M-Score is -2.95 as of Jul. 14, 2026. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 763 Medical Devices & Instruments companies, Nang Kuang Pharmaceutical Co ranks better than 75.75% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.95 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Nang Kuang Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

TPE:1752' s Beneish M-Score Range Over the Past 10 Years
Min: -2.96   Med: -2.74   Max: -2.31
Current: -2.95

During the past 13 years, the highest Beneish M-Score of Nang Kuang Pharmaceutical Co was -2.31. The lowest was -2.96. And the median was -2.74.


Nang Kuang Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Nang Kuang Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nang Kuang Pharmaceutical Co Beneish M-Score Chart

Nang Kuang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.52 -2.31 -2.66 -2.82 -2.95

Nang Kuang Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 -2.97 -3.03 -2.98 -2.95

TPE:1752 vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nang Kuang Pharmaceutical Co Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Nang Kuang Pharmaceutical Co's Beneish M-Score falls into.


TPE:1752
88GF Score
Nang Kuang Pharmaceutical Co Ltd TPE:1752
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nang Kuang Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Nang Kuang Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8764+0.528 * 0.956+0.404 * 0.8979+0.892 * 0.9829+0.115 * 0.996
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1366+4.679 * -0.057453-0.327 * 0.9521
=-2.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$365 Mil.
Revenue was 517.196 + 523.835 + 541.712 + 579.475 = NT$2,162 Mil.
Gross Profit was 180.655 + 167.817 + 200.552 + 219.835 = NT$769 Mil.
Total Current Assets was NT$1,493 Mil.
Total Assets was NT$3,823 Mil.
Property, Plant and Equipment(Net PPE) was NT$2,162 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$183 Mil.
Selling, General, & Admin. Expense(SGA) was NT$303 Mil.
Total Current Liabilities was NT$1,065 Mil.
Long-Term Debt & Capital Lease Obligation was NT$186 Mil.
Net Income was 73.816 + 46.644 + 51.935 + 72.019 = NT$244 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 179.674 + 50.735 + 94.697 + 138.972 = NT$464 Mil.
Total Receivables was NT$423 Mil.
Revenue was 579.207 + 579.889 + 512.296 + 528.469 = NT$2,200 Mil.
Gross Profit was 220.009 + 196.574 + 159.736 + 171.474 = NT$748 Mil.
Total Current Assets was NT$1,456 Mil.
Total Assets was NT$3,813 Mil.
Property, Plant and Equipment(Net PPE) was NT$2,169 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$183 Mil.
Selling, General, & Admin. Expense(SGA) was NT$271 Mil.
Total Current Liabilities was NT$1,143 Mil.
Long-Term Debt & Capital Lease Obligation was NT$168 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(364.536 / 2162.218) / (423.197 / 2199.861)
=0.168594 / 0.192374
=0.8764

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(747.793 / 2199.861) / (768.859 / 2162.218)
=0.339927 / 0.355588
=0.956

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1492.605 + 2161.602) / 3823.371) / (1 - (1455.987 + 2169.012) / 3812.874)
=0.044245 / 0.049274
=0.8979

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2162.218 / 2199.861
=0.9829

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(182.957 / (182.957 + 2169.012)) / (183.137 / (183.137 + 2161.602))
=0.077789 / 0.078105
=0.996

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(302.621 / 2162.218) / (270.884 / 2199.861)
=0.139959 / 0.123137
=1.1366

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((186.385 + 1064.79) / 3823.371) / ((167.63 + 1142.819) / 3812.874)
=0.327244 / 0.343691
=0.9521

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(244.414 - 0 - 464.078) / 3823.371
=-0.057453

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Nang Kuang Pharmaceutical Co has a M-score of -2.95 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.95 mean?
Nang Kuang Pharmaceutical Co (TPE:1752) has a Beneish M-Score of -2.95 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Nang Kuang Pharmaceutical Co and its competitors. According to the industry distribution chart, Nang Kuang Pharmaceutical Co ranks #185 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 24.2%.
Is Nang Kuang Pharmaceutical Co's Beneish M-Score too high?
Nang Kuang Pharmaceutical Co's current Beneish M-Score is -2.95. Based on the distribution chart, Nang Kuang Pharmaceutical Co ranks #185 out of 763 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nang Kuang Pharmaceutical Co ranks #185 out of 763 companies for Beneish M-Score. This places Nang Kuang Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Nang Kuang Pharmaceutical Co and its competitors. Nang Kuang Pharmaceutical Co's current Beneish M-Score is -2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current Beneish M-Score is -2.95. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current Beneish M-Score is -2.95 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?

Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62. GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for TPE:1752:

  • Beneish M-Score: -2.95
  • GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nang Kuang Pharmaceutical Co Business Description

Address Section 8, Civic Boulevard, 5th Floor, No. 205, Nangang District, Taipei, TWN, 115
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score

Get the complete analysis for TPE:1752

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.35
Price
NT$46.62
GF Value